659 related articles for article (PubMed ID: 33173437)
1. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
2. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
3. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
4. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
5. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
6. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
7. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Xiao Z; Liang J; Deng Q; Song C; Yang X; Liu Z; Shao Z; Zhang K; Wang X; Li Z
Int J Mol Med; 2021 Jan; 47(1):113-124. PubMed ID: 33155660
[TBL] [Abstract][Full Text] [Related]
8. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
9. Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models.
Cao L; Gao H; Gui S; Bai G; Lu R; Wang F; Zhang Y
J Neurooncol; 2014 Feb; 116(3):523-31. PubMed ID: 24407733
[TBL] [Abstract][Full Text] [Related]
10. Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line.
Leng L; Zhang Y
J Clin Neurosci; 2011 Dec; 18(12):1694-8. PubMed ID: 22015101
[TBL] [Abstract][Full Text] [Related]
11. Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
Ferraris J
Front Endocrinol (Lausanne); 2022; 13():1057749. PubMed ID: 36714572
[TBL] [Abstract][Full Text] [Related]
12. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Cao L; Gao H; Li P; Gui S; Zhang Y
Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679
[TBL] [Abstract][Full Text] [Related]
13. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.
Osamura RY; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
Liu X; Liu Y; Gao J; Feng M; Bao X; Deng K; Yao Y; Wang R
World Neurosurg; 2018 Jul; 115():94-98. PubMed ID: 29530699
[TBL] [Abstract][Full Text] [Related]
16. Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2016 Oct; 7(40):65602-65613. PubMed ID: 27564112
[TBL] [Abstract][Full Text] [Related]
17. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells.
Barcus CE; Holt EC; Keely PJ; Eliceiri KW; Schuler LA
PLoS One; 2015; 10(1):e0116891. PubMed ID: 25607819
[TBL] [Abstract][Full Text] [Related]
18. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
19. Association of prolactin receptor (PRLR) variants with prolactinomas.
Gorvin CM; Newey PJ; Rogers A; Stokes V; Neville MJ; Lines KE; Ntali G; Lees P; Morrison PJ; Singhellakis PN; Malandrinou FC; Karavitaki N; Grossman AB; Karpe F; Thakker RV
Hum Mol Genet; 2019 Mar; 28(6):1023-1037. PubMed ID: 30445560
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
